Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Appointed director
Quarterly results
Mirati Therapeutics, Inc. (MRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/12/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/11/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/10/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/10/2023 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"AGREEMENT AND PLAN OF MERGER among: MIRATI THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and VINEYARD MERGER SUB INC.,",
"AMENDMENT TO BYLAWS OF MIRATI THERAPEUTICS, INC. ARTICLE XV MISCELLANEOUS",
"ARTICLE XV MISCELLANEOUS",
"Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics",
"Voting and Support Agreement, by and among Bristol-Myers Squibb Company, Boxer Capital, LLC, and MVA Investors, LLC"
10/10/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/10/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
10/05/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
10/02/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer"
08/16/2023 SC 13D/A Boxer Capital, LLC reports a 15.9% stake in Mirati Therapeutics, Inc.
08/15/2023 4 Boxer Capital, LLC (See remarks) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Bought 57,533 shares @ $27.8, valued at $1.6M
Bought 1,201,440 shares @ $27.8, valued at $33.4M
08/15/2023 4 Boxer Capital, LLC (See remarks) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Bought 57,533 shares @ $27.8, valued at $1.6M
Bought 1,201,440 shares @ $27.8, valued at $33.4M
08/14/2023 4 Hasnain Faheem (Director) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Bought 10,791 shares @ $27.8, valued at $300k
08/10/2023 4 Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 22,297 shares @ $37, valued at $825k
08/10/2023 4 BAUM CHARLES M (Interim CEO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 54,054 shares @ $37, valued at $2M
08/10/2023 4 Hickey Benjamin (EVP, Chief Commercial Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 22,297 shares @ $37, valued at $825k
08/10/2023 4 Moriarty John B (Chief Legal Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 22,297 shares @ $37, valued at $825k
08/10/2023 4 Christensen Jamie (EVP & Chief Scientific Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 22,297 shares @ $37, valued at $825k
08/10/2023 4 Sandler Alan B. (Chief Medical Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 22,297 shares @ $37, valued at $825k
08/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Underwriting Agreement",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP",
"MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING",
"MIRATI THERAPEUTICS ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING"
08/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results, Appointed a new director
Docs: "FORM 8-K",
"Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates",
"Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek",
"Corporate Presentation"
07/21/2023 8-K Quarterly results
06/02/2023 4 Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Sold 4,647 shares @ $37.06, valued at $172.2k
05/24/2023 4 Christensen Jamie (EVP & Chief Scientific Officer) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Sold 619 shares @ $45.2905, valued at $28k
05/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®"
05/12/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates"
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 ARS Form ARS - Annual Report to Security Holders:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy